Navigation Links
Sequenom Announces Participation at UBS Global Life Sciences Conference
Date:9/13/2011

SAN DIEGO, Sept. 13, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the UBS Global Life Sciences Conference at the Grand Hyatt New York Hotel in New York City September 19-21, 2011.

Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Monday, September 19, 2011 beginning at 3:30 p.m. ET, to provide an overview of and update on the Company.  The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com.  An audio replay will be available for 30 days following the initial presentation web cast.  

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

SEQUENOM ® is a trademark of Sequenom, Inc. All other trademarks and service marks are the property of t
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sequenom Announces Participation at William Blair and Company 5th Annual Emerging Growth Stock Conference
2. Sequenom Announces Multi-Year Supply Agreement With Illumina
3. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
4. Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
5. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Sequenom CMM Commences Pivotal Clinical Validation Study for Its SensiGene Trisomy 21 Laboratory Developed Test
7. Sequenom to Present at Two Financial Conferences in November
8. Sequenom Announces Date of Second Quarter 2010 Financial Results and Conference Call
9. Sequenom to Present at the Jefferies 2010 Global Life Sciences Conference
10. Sequenom Announces Final Approval of Settlement in Class Action Securities Lawsuit
11. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... financial results for the fourth quarter and full year ... a transformative year for PTC. We are now a ... RNA-targeted therapies in the rare disease space," stated Stuart ... "We are proud to bring the first treatment for ...
(Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
(Date:2/27/2015)... TORONTO , Feb. 27, 2015  Bionik Laboratories ... (the "Company"), announced today that it acquired Bionik Laboratories, ... Laboratories"), and completed the sale to qualified accredited investors ... for aggregate gross proceeds of approximately $6.2 million. Shares ... quoted on the OTC Markets under the symbol "DWTPD" ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... Duncan Fletcher of Game Change ... and Shannon Leinert about the benefits of athlete development ... underscores some of the unique challenges that athletes face ... on-field and future success. , Fletcher became involved in ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... BELLEVUE, Wash., Sept. 11 The Citizens,Committee for the ... with,Oklahoma Sen. Tom Coburn that there is a serious ... Suicide Prevention Act -- that could,ultimately prevent military veterans ... defend., The problem, as pointed out by Sen. ...
... Thanks to a $1.6 million grant from the Welch ... launching a new initiative to develop innovative computational and ... drugs and molecular tools for biomedical science. , The ... Gulf Coast Consortium for Chemical Genomics (GCC CG) to ...
... with the breast cancer susceptibility gene BRCA1 often remove ... they believe fuels cancer growth. Yet they also know ... ovarian cancer that might develop. That paradox has led ... involved in cancer development and whether removal of ovaries ...
... Inc. (Pink Sheets: MSITF) wishes to announce that it has,completed ... Hepatitis C,test kit in Europe. Completion of this testing will ... EU approval would allow the Company to expand its ... It is anticipated that,when EU approval is received that it ...
... Sept. 11 Responding to a lawsuit by ... national medical,licensing examination, the National Board of Medical ... the needs of breastfeeding mothers as well as,other ... first priority for this test, accepted as evidence ...
... treatment, reseachers say , TUESDAY, Sept. 11 (HealthDay News) ... believe they may have found the disease,s genetic on/off ... to the development of better treatments, the team said. ... mouse model for schizophrenia by inserting the mutant Disrupted-In-Schizophrenia ...
Cached Medicine News:Health News:CCRKBA Backs Sen. Coburn's Opposition to Tenets of H.R. 327 2Health News:Welch Foundation gives $1.6 million for drug discovery research 2Health News:Welch Foundation gives $1.6 million for drug discovery research 3Health News:New clues to breast cancer development in high-risk women 2Health News:New clues to breast cancer development in high-risk women 3Health News:New clues to breast cancer development in high-risk women 4Health News:Medical Services International Inc. Completes Testing for European Union (EU) Application 2Health News:Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test 2Health News:Schizophrenia Gene May Have On/Off Switch 2
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: